Thermo Fisher and Mainz Biomed Collaborate on Colorectal Cancer Screening Innovation

• Thermo fisher and Mainz Biomed have entered a collaboration to advance colorectal cancer screening technologies.

• The partnership aims to develop a next-generation mRNA-based test targeting early detection, including precancerous lesions.

Thermo Fisher Scientific and Mainz Biomed N.V., a company focused on molecular genetic diagnostics for cancer detection, has announced a new collaboration. Through this agreement, the companies will work together to develop Mainz Biomed’s next-generation mRNA-based screening test for colorectal cancer (CRC), leveraging Thermo Fisher’s technology and expertise.

The collaboration will focus on the development of Mainz Biomed’s proprietary assays designed for early colorectal cancer detection, including precancerous conditions like advanced adenomas. The project will use Thermo Fisher’s advanced technologies, including instrumentation and data processing systems, in Mainz Biomed’s laboratories in Mainz, Germany.

“This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a home collection colorectal screening tool with highly effective detection of adenomas,” said Guido Baechler, CEO of Mainz Biomed. He added that Thermo Fisher’s technologies would accelerate the availability of this innovative screening solution globally.

Peter Jacobs, Thermo Fisher’s Director of EMEA Clinical Business Development, expressed optimism about the partnership’s potential to deliver impactful advancements, noting that the collaboration “will be able to achieve rapid progress and deliver innovative new assays for the global clinical marketplace.”